Skip to content
DataLookout
Menu

NCT07919028

A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006)

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Area Under the Curve From Time 0 to the Next Dosing Interval (AUC0-tau) of MK-7602
Timeframe: At designated timepoints (up to approximately 21 days)
Maximum Plasma Concentration (Cmax) of MK-7602
Timeframe: At designated timepoints (up to approximately 21 days)
Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 2 months
Number of Participants Who Discontinue Study Intervention Due to an AE
Timeframe: Up to approximately 20 days

Secondary (2)

AUC0-tau of MK-7602
Cmax of MK-7602

Arms and interventions

Period 1: MK-7602Experimental

Participants will receive an oral dose of MK-7602 once daily on Days 1, 2, and 3 of Period 1.

Period 2: MK-7602 + PyronaridineExperimental

Participants will receive oral doses of MK-7602 and pyronaridine once daily on Days 1, 2, and 3 of Period 2.

Drugs: MK-7602, Pyronaridine